NGD 971

Drug Profile

NGD 971

Alternative Names: CP457920; NGD 97-1

Latest Information Update: 27 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurogen Corporation
  • Developer Neurogen Corporation; Pfizer
  • Class Antidementias; Neuroprotectants; Small molecules
  • Mechanism of Action GABA A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Jan 2011 Discontinued - Phase-II for Vascular dementia in USA (unspecified route)
  • 10 May 2004 Discontinued - Phase-II for Alzheimer's disease in USA (unspecified route)
  • 05 May 2004 Data presented at the 56th Annual Meeting of the American Academy of Neurology (AAN-2004) have been added to the Alzheimer's disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top